Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps

Omalizumab is a biological drug targeting circulating IgE, approved for use in allergic asthma, chronic spontaneous urticaria, and recently for chronic rhinosinusitis with nasal polyps, with good efficacy in all these settings. Some concerns about omalizumab safety have been raised as its use has be...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Diego Bagnasco, MD, PhD, Rikki Frank Canevari, MD, Stefano Del Giacco, MD, Silvia Ferrucci, MD, Paolo Pigatto, MD, Paolo Castelnuovo, MD, Gian Luigi Marseglia, MD, Arzu Didem Yalcin, MD, Girolamo Pelaia, MD, Giorgio Walter Canonica, MD
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2022-12-01
Serier:	World Allergy Organization Journal
Fag:	Severe asthma Omalizumab Cancer Anti IgE Monoclonal antibodies
Online adgang:	http://www.sciencedirect.com/science/article/pii/S1939455122000977
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!